Table 3 Incidence of adverse events
| MPC + HA (n = 11) | HA alone (n = 6) | |
|---|---|---|
| Total number of adverse events | 94 | 39 |
| Non-serious, n (%) | 92 (97.9) | 39 (100.0) |
| Serious, n (%) | 2 (2.1)# | 0 (0.0) |
| Adverse events by system organ class*, n (grade) | ||
| Musculoskeletal and connective tissue disorders | 11 (2) | 6 (1) |
| General disorders and administration site conditions | 3 (2) | 1 (1) |
| Injury, poisoning, and procedural complications | 2 (1) | 2 (1) |
| Infections and infestations | 1 (1) | 1 (1) |
| Respiratory, thoracic, and mediastinal disorders | 1 (1) | 0 |
| Immune system disorders | 2 (2) | 1 (2) |
